Cancer stem cells are often responsible for leading to metastasis and chemo-resistance, two of the most dangerous cancer-pathways. Stems cells can continue developing even when primary tumor cells are targeted. However, Vaxil’s immunotherapy products expose peptides which are expressed on cancer stem cells and therefore intended to harness the immune system to target even the cancer stem cells, in addition to targeting the primary tumor sites.
VAXIL – Creating the ideal immunotherapy
Inducing a Broad
Cancer ResistanceLearn More
Immune ResponseLearn More
Cancer Stem CellsLearn More
First Ever SP-Specific
Antibody PlatformLearn More
Vaxil’s Lead Products and Orphan Drug Status
Vaxil believes its immunotherapy platform allows it to target high profile cancer antigens in a uniquely superior manner, all designed to possess the novel advantages described above. Vaxil’s first test of its VaxHit™platform is its ImMucin™ lead immunotherapy product.